Table 1 Baseline characteristics and summary of findings from data of the 80 patients analysed in the study.

Age (years)

37.5 (SD:9.0),(n = 80)

38.0 (SD:8.5),(n = 29)

37 (SD:9.0),(n = 33)

33.5 (SD:10.2),(n = 18)

Sex

Male: 20 Female: 60

Male: 8 Female:21

Male:7 Female:26

Male: 5 Female:13

BMI (kg/m²)

22.6 (SD: 3.6),(n = 80)

22.4 (SD:3.9), (n = 29)

23.2 (SD:3.4), (n = 33)

22 (SD:3.0),(n = 18)

Initial CD4 count (×10⁶ l)

128.5 (IQR:142),(n = 80)

113 (IQR:114),(n = 29)

131(IQR:148),(n = 33)

158 (IQR:9),(n = 18)

Initial viral load(copies/ml)

86450 (IQR:2.3 × 10⁶),(n = 76)

96600 (IQR:2.2 × 10⁶),(n = 27)

84900 (IQR:2.4 × 10⁶),(n = 33)

86500 (IQR:2.1 × 10⁶),(n = 16)

Presence of side effects(%)

84 (n = 67) *

76 (n = 22)

85 (n = 28)

94 (n = 17)

EFV concentrations (μg/l)

3980 (IQR:4476),(n = 80)*

2260 (IQR:3411),(n = 29) **

3858(IQR:2385),(n = 33)**

7136(IQR:3623),(n = 18)**